Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

EDGAR H. CASTELLANOS MD A MEDICAL CORPORATION

NPI: 1275689432 · SALINAS, CA 93906 · Family Medicine Physician · NPI assigned 01/28/2007

$2.15M
Total Medicaid Paid
45,442
Total Claims
42,037
Beneficiaries
16
Codes Billed
2018-01
First Month
2024-11
Last Month

Provider Details

Authorized OfficialCASTELLANOS, EDGAR (PRESIDENT)
NPI Enumeration Date01/28/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 5,879 $339K
2019 7,571 $396K
2020 7,615 $371K
2021 8,002 $324K
2022 7,011 $265K
2023 5,505 $220K
2024 3,859 $238K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 10,854 9,987 $1.30M
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 17,002 15,576 $551K
99215 Prolong outpt/office vis 3,539 3,247 $236K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular 1,717 1,631 $33K
81025 2,524 2,369 $8K
20553 138 126 $6K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 74 65 $5K
J1885 Injection, ketorolac tromethamine, per 15 mg 1,343 1,228 $4K
99205 Prolong outpt/office vis 37 37 $3K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 307 293 $3K
80305 4,580 4,312 $3K
81000 3,226 3,069 $3K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 14 14 $2K
90686 44 44 $713.50
82948 30 27 $83.20
J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg 13 12 $38.91